Adamis pharmaceuticals issues letter to stockholders

San diego, july 21, 2022 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from chief executive officer david j. marguglio.
ADMP Ratings Summary
ADMP Quant Ranking